Sponsored Links
| Symphogen Presents Results From The First Clinical Trial With Sym004 At ASCO |
 |
 |
 |
| Medical News - Colorectal Cancer | |||
|
Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004. Based on the data, the poster authors concluded that Sym004 is well tolerated, and shows preliminary signs of clinical effect... Read more: Colorectal Cancer News From Medical News Today
|